思创医惠涉嫌欺诈发行证券 被公安局调查

Core Viewpoint - Sichuan Medical Technology Co., Ltd. (思创医惠) is under investigation by Hangzhou Public Security Bureau for suspected fraudulent issuance of securities, marking the first time the company has mentioned such an investigation since its listing in April 2010 [1][4]. Group 1: Investigation Details - On August 14, Sichuan Medical Technology received a "Notice of Evidence Collection" from Hangzhou Public Security Bureau regarding the investigation into its suspected fraudulent issuance of securities [4]. - The case is currently in the investigation stage, and no definitive conclusions have been reached yet [4]. Group 2: Financial Irregularities - The company has been found to have inflated its financial figures through fraudulent activities, including a total of 34.93 million yuan in inflated revenue and 33.02 million yuan in inflated profits for 2019, and 60.96 million yuan in inflated revenue and 52.37 million yuan in inflated profits for the first three quarters of 2020 [6][8]. - The administrative penalty decision issued by Zhejiang Securities Regulatory Bureau on January 8, 2024, confirmed that the company had fabricated significant false content in its public offering documents and that its 2019 and 2020 annual reports contained false records [8]. Group 3: Fundraising and Investment Issues - Sichuan Medical Technology has faced continuous losses in recent years, with net profits of -878 million yuan in 2022, -874 million yuan in 2023, and -501 million yuan in 2024 [9][14]. - The company raised funds through non-public stock issuance in 2019 and convertible bonds in 2021, but most of the planned investment projects have not been fully executed, with only 30.54 million yuan out of a planned 56.54 million yuan invested [9][10]. - Specific projects, such as the Internet + AI medical innovation operation service project, have seen minimal investment compared to their planned amounts, with only 228,550 yuan invested out of a planned 3.33 billion yuan [11][13].